A novel multi-lineage human intestinal organoid screening platform for drug discovery and preclinical testing

Active Project Grant Awarded Last action

Award ID
R44TR005379
Recipient
Awarding agency
Obligated
$1,046,897

Award facts

Completion date 19% complete
Place of performance
Aurora, CO 80045, USA

Award details come from USAspending.gov.

About this award

The National Center for Advancing Translational Sciences awarded Intero Biosystems Inc. $1.046897 million in project grant funding on July 1, 2026, under CFDA 93.350.

Intero Biosystems will develop a stem cell-derived human intestinal organoid platform for drug discovery and preclinical testing. The platform incorporates multiple cell types of the native intestine to model both normal intestinal function and disease processes. Phase II work will scale production methods and validate assay readouts for high-throughput screening, establishing standardized quality control, shelf-life, and cryopreservation benchmarks to enable distribution for industrial use. The recipient will expand cytotoxicity screening to detect compounds with selective or partial effects on different intestinal cell types and evaluate antifibrotic efficacy in models of acute, chronic, and immune-mediated fibrosis against FDA-approved and experimental therapies. Phase I established robust assays for intestinal toxicity and fibrosis with strong reproducibility.

Performance will occur in Aurora, Colorado, with a period of performance from July 1, 2026, through June 30, 2028. The funding supports the NCATS mission to develop innovations that reduce bottlenecks in the translational research pipeline and accelerate delivery of new drugs and diagnostics to patients.

Description

Abstract
Over 90% of drug candidates fail in clinical trials, resulting in high costs and delayed access to therapies. These failures are driven by the limitations of current preclinical models, which rely on animal systems that do not fully capture human biology or simple cell monolayers that lack the complexity of native tissues. There is an urgent need for human-relevant models that better predict drug toxicity and efficacy. Intero biosystems has developed the first stem cell-derived human intestinal organoid (HIO) platform that incorporates multiple cell types of the native intestine. This multicellular architecture enables modeling of both normal intestinal function and disease processes that are not possible in traditional systems. In phase I, we successfully established robust assays for intestinal toxicity and fibrosis with strong reproducibility and focus of this phase II proposal is to scale production methods and validate assay readouts to meet the market needs for high-throughput screening projects. The efforts of this project will establish standardized quality control, shelf life, and cryopreservation benchmarks to ensure consistent performance and enable distribution for industrial use. Additionally, we will expand cytotoxicity screening to detect compounds with selective or partial effects on different intestinal cell types. To complement overt cytotoxic assessments, we will evaluate antifibrotic efficacy in models of acute, chronic, and immune-mediated fibrosis, testing FDA-approved and experimental therapies. Successful completion of this project will position the HIO platform as a scalable, predictive, and commercially viable tool for drug discovery. By capturing the cellular diversity and functional complexity of the intestine "in a dish," this system offers the potential to transform preclinical testing, reduce reliance on animal studies, and accelerate the development of safe and effective therapies.

Quick answers

Who received award R44TR005379?

R44TR005379 was awarded to Intero Biosystems Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on July 1, 2026.

How much is award R44TR005379 worth?

$1,046,897 has been obligated on R44TR005379.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award